<DOC>
	<DOCNO>NCT01815255</DOCNO>
	<brief_summary>This study ass safety efficacy generic TDF Governmental Pharmaceutical Organization ( GPO ) HIV-infected child</brief_summary>
	<brief_title>TDF Long Term Study</brief_title>
	<detailed_description>TDF nucleotide reverse transcriptase inhibitor ( NRTI ) take per day continue good efficacy even patient resistance NNRTI absence K65R mutation . TDF choice patient NRTI resistance , require once-daily regimen improve adherence . Currently , TDF approve US FDA child less 18 year , pediatrician use TDF child treatment failure limitation appropriate pediatric ARV . The Thai national guideline pediatric 2009 recommend use TDF child fail first line therapy multi-NRTI mutation 30 kilogram tanner stage 4 . However , problem pediatric TDF formulation . The available preparation 300 mg tear drop tablet , cut half , may increase dose error , less 18-37 % . This affect blood level and/or toxicity . Therefore , Thai Governmental Pharmaceutical Organization ( GPO ) produce generic TDF formulation use HIV-infected child . This study ass safety efficacy information child use generic pediatric TDF formulation .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>child change TDF due adherence problem treatment failure child already TDF due clinical indication child/caretaker refuse participate study adhere study schedule</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>TDF-based regimen</keyword>
	<keyword>HIV-infected child</keyword>
	<keyword>Thai</keyword>
	<keyword>generic</keyword>
	<keyword>safety efficacy</keyword>
	<keyword>renal status</keyword>
	<keyword>To assess effect TDF renal problem HIV-infected child receive TDF-based daily regimen</keyword>
	<keyword>To compare effectiveness clinical usefulness different tool adherence</keyword>
</DOC>